Register non-binding interest to participate in Elicera's next round of financing

Elicera Therapeutics develops cell and gene therapies in immuno-oncology

Elicera Therapeutics develops four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields.

Elicera's lead programs in each respective field:

ELC-100 ELC-301

Get to know Elicera Therapeutics

Elicera's strengths are based on a deep understanding of how cells and viruses can be genetically engineered to trigger a powerful immune response to cancer

About Elicera

Training the immune system to fight cancer

Unlike traditional cancer therapies, such as radiation, surgery and chemotherapy, immuno-oncology is about training the body's own immune system to fight cancer.

Immuno-oncology

Ongoing clinical study

Uppsala University is currently sponsoring an ongoing clinical phase I/II-study with Elicera's oncolytic virus, ELC-100, in neuroendocrine tumors. In addition, a second clinical phase I/II-study with CAR T-cell therapy, ELC-301, in B-cell lymphoma, is under planning.

Technology Pipeline

Notice of interest

Register a non-binding interest to participate in Elicera's next round of financing, tentatively planned for spring 2021. We thank you for your interest and will contact you when it becomes relevant.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.